Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives
Open Access
- 1 April 2009
- journal article
- review article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 5 (1) , 377-387
Abstract
Peer reviewed article authored by (Madhuri Devabhaktuni, Sripal Bangalore). Read article or submit your manuscript for publishing.Keywords
This publication has 57 references indexed in Scilit:
- Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study)Journal of Human Hypertension, 2008
- A Randomized, Placebo‐Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond TrialThe Journal of Clinical Pharmacology, 2007
- Effect of Food on the Bioavailability of Amlodipine Besylate/Atorvastatin Calcium Combination TabletThe Journal of Clinical Pharmacology, 2006
- The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) TrialHypertension, 2006
- Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)International Journal of Cardiology, 2006
- Intermolecular Differences of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Contribute to Distinct Pharmacologic and Pleiotropic ActionsThe American Journal of Cardiology, 2005
- Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapyExpert Opinion on Pharmacotherapy, 2004
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Evidence for a Synergistic Effect of Calcium Channel Blockers With Lipid-Lowering Therapy in Retarding Progression of Coronary Atherosclerosis in Symptomatic Patients With Normal to Moderately Raised Cholesterol LevelsArteriosclerosis, Thrombosis, and Vascular Biology, 1996